BONESUPPORT announced 12-month follow-up data from an on-going clinical trial investigating the safety and efficacy of CERAMENT|G in chronic bone infection and the completeness of bone healing after surgery. CERAMENT|G is an injectable antibiotic eluting bone substitute. The results also showed evidence of ongoing bone remodeling in 80 percent of the remaining patients.
“This evidence reinforces our belief that CERAMENT|G has the potential to impact the surgical strategy for managing osteomyelitis, by providing a more effective delivery of antibiotics with concomitant full bone healing in a one-stage procedure, thereby reducing treatment time, minimizing surgical interventions and lowering healthcare costs,” said Lloyd Diamond, CEO of BONESUPPORT.
More articles on devices:
Zimmer purchases biologic therapeutics company ETEX
Medtronic to aid Syrian refugees in Jordan
Bacterin CEO to appear on FOX Business Network’s Open Bell
